FC
PVLA

Financial Consulate’s Palvella Therapeutics PVLA Stock Holding History

Financial Consulate’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$765 Hold
5
– – ﹤0.01% 1211
2026
Q1 		$624 Hold
5
– – ﹤0.01% 1194
2025
Q4 		$524 Hold
5
– – ﹤0.01% 1157
2025
Q3 		$314 Buy
+5
New +$223 ﹤0.01% 1110

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Financial Consulate's PVLA Position: Q2 2026 in Review

Financial Consulate held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 5 shares worth $765. The position accounts for ﹤0.01% of the portfolio, ranked #1211.

Financial Consulate first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Financial Consulate held 5 shares of Palvella Therapeutics worth $765 as of Q2 2026.
  • Financial Consulate left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #1211 holding.
  • Financial Consulate first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.